Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer.
Standard
Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer. / Witzel, Isabell; Kantelhardt, Eva Johanna; Milde-Langosch, Karin; Henningsen, Maike; Zeitz, Julia; Harbeck, Nadia; Jänicke, Fritz; Müller, Volkmar.
In: ONKOLOGIE, Vol. 34, No. 6, 6, 2011, p. 304-308.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer.
AU - Witzel, Isabell
AU - Kantelhardt, Eva Johanna
AU - Milde-Langosch, Karin
AU - Henningsen, Maike
AU - Zeitz, Julia
AU - Harbeck, Nadia
AU - Jänicke, Fritz
AU - Müller, Volkmar
PY - 2011
Y1 - 2011
N2 - Background: With the more effective control of visceral metastases in patients with metastatic breast cancer (MBC), an increasing number of patients face brain metastases (BM). The aim of this retrospective analysis was to investigate the incidence and factors affecting the prognosis of patients with BM under trastuzumab treatment for MBC. Patients and Methods: A total of 75 HER2positive patients treated with trastuzumab for MBC were included. Results are discussed in the context of the current literature. Results: Patients who developed BM (n = 29) had longer median progression-free survival (PFS) during first-line chemotherapy and longer overall survival (OS) after diagnosis of MBC than 46 patients without BM (PFS: 27 vs. 14 months, p = 0.039; OS: 46 vs. 18 months, p = 0.067). Median survival of patients with continuation of trastuzumab after diagnosis of BM was longer than survival of patients with discontinuation of trastuzumab treatment after BM (18 vs. 3 months, p = 0.006). Survival of patients who were treated with surgery and radiotherapy for BM was better compared with radiotherapy alone (9 vs. 5 months, p = not significant) or best supportive care (9 vs. 2 months, p = 0.049). Conclusions: Continuation of trastuzumab treatment as well as resection of BM seem to give further benefit in the treatment of patients with HER2-overexpressing MBC.
AB - Background: With the more effective control of visceral metastases in patients with metastatic breast cancer (MBC), an increasing number of patients face brain metastases (BM). The aim of this retrospective analysis was to investigate the incidence and factors affecting the prognosis of patients with BM under trastuzumab treatment for MBC. Patients and Methods: A total of 75 HER2positive patients treated with trastuzumab for MBC were included. Results are discussed in the context of the current literature. Results: Patients who developed BM (n = 29) had longer median progression-free survival (PFS) during first-line chemotherapy and longer overall survival (OS) after diagnosis of MBC than 46 patients without BM (PFS: 27 vs. 14 months, p = 0.039; OS: 46 vs. 18 months, p = 0.067). Median survival of patients with continuation of trastuzumab after diagnosis of BM was longer than survival of patients with discontinuation of trastuzumab treatment after BM (18 vs. 3 months, p = 0.006). Survival of patients who were treated with surgery and radiotherapy for BM was better compared with radiotherapy alone (9 vs. 5 months, p = not significant) or best supportive care (9 vs. 2 months, p = 0.049). Conclusions: Continuation of trastuzumab treatment as well as resection of BM seem to give further benefit in the treatment of patients with HER2-overexpressing MBC.
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Risk Factors
KW - Treatment Outcome
KW - Risk Assessment
KW - Survival Analysis
KW - Survival Rate
KW - Germany/epidemiology
KW - Antibodies, Monoclonal, Humanized
KW - Antineoplastic Agents/therapeutic use
KW - Antibodies, Monoclonal/therapeutic use
KW - Brain Neoplasms/drug therapy/mortality/secondary
KW - Breast Neoplasms/drug therapy/mortality
KW - Carcinoma/drug therapy/mortality/secondary
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Risk Factors
KW - Treatment Outcome
KW - Risk Assessment
KW - Survival Analysis
KW - Survival Rate
KW - Germany/epidemiology
KW - Antibodies, Monoclonal, Humanized
KW - Antineoplastic Agents/therapeutic use
KW - Antibodies, Monoclonal/therapeutic use
KW - Brain Neoplasms/drug therapy/mortality/secondary
KW - Breast Neoplasms/drug therapy/mortality
KW - Carcinoma/drug therapy/mortality/secondary
M3 - SCORING: Journal article
VL - 34
SP - 304
EP - 308
JO - ONKOLOGIE
JF - ONKOLOGIE
SN - 0378-584X
IS - 6
M1 - 6
ER -
